About Us
Our Technology
Our Pipeline
Patients
Our News
More
Akamis Bio’s latest news, events and updates.
Apr 3, 2025
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer
Dec 17, 2024
Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership
Oct 23, 2024
Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload
October 3, 2023
Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer
July 6, 2023
Akamis Bio Strengthens Leadership Team with Key Executive Appointments